Summary: Low back pain is one of the most common reasons behind visits to neurology offices. Despite the correlation between older age and the incidence of low back pain, the largest group of patients worldwide are those between the ages of 50 and 54. Pharmacotherapy of spinal pain, including sacroiliac pain, still remains a significant challenge in modern medicine. Despite some attempts to describe new treatment standards, the efficacy of the drugs used to date has repeatedly proven insufficient, with the health consequences of pain chronification. Although international recommendations for non-pharmacological therapies are mostly unanimous, a considerable discrepancy exists between the recommendations provided in the guidelines in individual countries and the recommendations and practical application of recommended pharmacological therapies, which is mainly applicable to myorelaxants. From a pharmacological point of view, the described group of drugs includes preparations with a peripheral effect, i.e., peripheral muscle relaxants used in anesthesiology (e.g., pancuronium), and with a central effect, so-called myorelaxants, e.g., pridinol. Clinical trials indicate that pridinol add-on therapy is effective in treating acute spinal pain syndromes.